Morning versus random timing of immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study compares giving pembrolizumab (an immunotherapy drug) in the morning versus at a random time during the day, to see if timing affects how well it works or side effects. If you're eligible, you'll receive standard pembrolizumab treatment, but your infusion time will be assigned by the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer that has spread (metastatic).
- Your tumor tests positive for a high level of PD-L1 (a protein that helps cancer hide from the immune system) — at least 50%.
- You are eligible to receive pembrolizumab (an immunotherapy drug) as your only cancer treatment.
- You are generally able to care for yourself (ECOG performance status 0–2).
- Your blood test results meet the study's requirements for kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
This trial is testing whether the time of day you receive chemotherapy and pembrolizumab (immunotherapy) affects how well they work against triple-negative breast cancer. It's for people who will get these treatments before surgery.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
Hear when a new Metastatic Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.